Drug Search Results
More Filters [+]

Eniluracil

Alternative Names: eniluracil, adh-300004, adh300004, adh 300004, PCS6422, PCS-6422, PCS 6422
Latest Update: 2024-09-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPD Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Fennec Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eniluracil

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Triple Negative Breast Cancer

Phase 1: Gastrointestinal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PCS6422-BC-01

P2

Recruiting

Triple Negative Breast Cancer

2026-09-01

PCS6422-GI-01

P1

Completed

Gastrointestinal Cancer

2024-06-12

Recent News Events